Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy

Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Biao Huang [verfasserIn] Yi Zhang [verfasserIn] Liang Wang [verfasserIn] Qingqing Wu [verfasserIn] Ting Li [verfasserIn] Jue Zhang [verfasserIn] Qiuhua Zhang [verfasserIn] Huiming Sheng [verfasserIn] Jiandong Bao [verfasserIn] Zhigang Hu [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	phospholipase A2 receptor autoantibodies thyroid disease autoimmune nephropathy

Übergeordnetes Werk:	In: Frontiers in Immunology - Frontiers Media S.A., 2011, 11(2020)
Übergeordnetes Werk:	volume:11 ; year:2020

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3389/fimmu.2020.00837

Katalog-ID:	DOAJ008658684

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ008658684
003	DE-627
005	20230310012822.0
007	cr uuu---uuuuu
008	230225s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3389/fimmu.2020.00837 \|2 doi
035			\|a (DE-627)DOAJ008658684
035			\|a (DE-599)DOAJbb78e04da73a42688a1189320e2a185c
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC581-607
100	0		\|a Biao Huang \|e verfasserin \|4 aut
245	1	0	\|a Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy.
650		4	\|a phospholipase A2 receptor
650		4	\|a autoantibodies
650		4	\|a thyroid disease
650		4	\|a autoimmune
650		4	\|a nephropathy
653		0	\|a Immunologic diseases. Allergy
700	0		\|a Biao Huang \|e verfasserin \|4 aut
700	0		\|a Yi Zhang \|e verfasserin \|4 aut
700	0		\|a Liang Wang \|e verfasserin \|4 aut
700	0		\|a Qingqing Wu \|e verfasserin \|4 aut
700	0		\|a Ting Li \|e verfasserin \|4 aut
700	0		\|a Jue Zhang \|e verfasserin \|4 aut
700	0		\|a Qiuhua Zhang \|e verfasserin \|4 aut
700	0		\|a Huiming Sheng \|e verfasserin \|4 aut
700	0		\|a Jiandong Bao \|e verfasserin \|4 aut
700	0		\|a Zhigang Hu \|e verfasserin \|4 aut
773	0	8	\|i In \|t Frontiers in Immunology \|d Frontiers Media S.A., 2011 \|g 11(2020) \|w (DE-627)657998354 \|w (DE-600)2606827-8 \|x 16643224 \|7 nnns
773	1	8	\|g volume:11 \|g year:2020
856	4	0	\|u https://doi.org/10.3389/fimmu.2020.00837 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/bb78e04da73a42688a1189320e2a185c \|z kostenfrei
856	4	0	\|u https://www.frontiersin.org/article/10.3389/fimmu.2020.00837/full \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1664-3224 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 11 \|j 2020

Indexfelder

author_variant	b h bh b h bh y z yz l w lw q w qw t l tl j z jz q z qz h s hs j b jb z h zh
matchkey_str	article:16643224:2020----::hshlpsarcpoatatbdeaaoesrlgclimrefruomuehri
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	10.3389/fimmu.2020.00837 doi (DE-627)DOAJ008658684 (DE-599)DOAJbb78e04da73a42688a1189320e2a185c DE-627 ger DE-627 rakwb eng RC581-607 Biao Huang verfasserin aut Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy. phospholipase A2 receptor autoantibodies thyroid disease autoimmune nephropathy Immunologic diseases. Allergy Biao Huang verfasserin aut Yi Zhang verfasserin aut Liang Wang verfasserin aut Qingqing Wu verfasserin aut Ting Li verfasserin aut Jue Zhang verfasserin aut Qiuhua Zhang verfasserin aut Huiming Sheng verfasserin aut Jiandong Bao verfasserin aut Zhigang Hu verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 11(2020) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:11 year:2020 https://doi.org/10.3389/fimmu.2020.00837 kostenfrei https://doaj.org/article/bb78e04da73a42688a1189320e2a185c kostenfrei https://www.frontiersin.org/article/10.3389/fimmu.2020.00837/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020
spelling	10.3389/fimmu.2020.00837 doi (DE-627)DOAJ008658684 (DE-599)DOAJbb78e04da73a42688a1189320e2a185c DE-627 ger DE-627 rakwb eng RC581-607 Biao Huang verfasserin aut Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy. phospholipase A2 receptor autoantibodies thyroid disease autoimmune nephropathy Immunologic diseases. Allergy Biao Huang verfasserin aut Yi Zhang verfasserin aut Liang Wang verfasserin aut Qingqing Wu verfasserin aut Ting Li verfasserin aut Jue Zhang verfasserin aut Qiuhua Zhang verfasserin aut Huiming Sheng verfasserin aut Jiandong Bao verfasserin aut Zhigang Hu verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 11(2020) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:11 year:2020 https://doi.org/10.3389/fimmu.2020.00837 kostenfrei https://doaj.org/article/bb78e04da73a42688a1189320e2a185c kostenfrei https://www.frontiersin.org/article/10.3389/fimmu.2020.00837/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020
allfields_unstemmed	10.3389/fimmu.2020.00837 doi (DE-627)DOAJ008658684 (DE-599)DOAJbb78e04da73a42688a1189320e2a185c DE-627 ger DE-627 rakwb eng RC581-607 Biao Huang verfasserin aut Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy. phospholipase A2 receptor autoantibodies thyroid disease autoimmune nephropathy Immunologic diseases. Allergy Biao Huang verfasserin aut Yi Zhang verfasserin aut Liang Wang verfasserin aut Qingqing Wu verfasserin aut Ting Li verfasserin aut Jue Zhang verfasserin aut Qiuhua Zhang verfasserin aut Huiming Sheng verfasserin aut Jiandong Bao verfasserin aut Zhigang Hu verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 11(2020) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:11 year:2020 https://doi.org/10.3389/fimmu.2020.00837 kostenfrei https://doaj.org/article/bb78e04da73a42688a1189320e2a185c kostenfrei https://www.frontiersin.org/article/10.3389/fimmu.2020.00837/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020
allfieldsGer	10.3389/fimmu.2020.00837 doi (DE-627)DOAJ008658684 (DE-599)DOAJbb78e04da73a42688a1189320e2a185c DE-627 ger DE-627 rakwb eng RC581-607 Biao Huang verfasserin aut Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy. phospholipase A2 receptor autoantibodies thyroid disease autoimmune nephropathy Immunologic diseases. Allergy Biao Huang verfasserin aut Yi Zhang verfasserin aut Liang Wang verfasserin aut Qingqing Wu verfasserin aut Ting Li verfasserin aut Jue Zhang verfasserin aut Qiuhua Zhang verfasserin aut Huiming Sheng verfasserin aut Jiandong Bao verfasserin aut Zhigang Hu verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 11(2020) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:11 year:2020 https://doi.org/10.3389/fimmu.2020.00837 kostenfrei https://doaj.org/article/bb78e04da73a42688a1189320e2a185c kostenfrei https://www.frontiersin.org/article/10.3389/fimmu.2020.00837/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020
allfieldsSound	10.3389/fimmu.2020.00837 doi (DE-627)DOAJ008658684 (DE-599)DOAJbb78e04da73a42688a1189320e2a185c DE-627 ger DE-627 rakwb eng RC581-607 Biao Huang verfasserin aut Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy. phospholipase A2 receptor autoantibodies thyroid disease autoimmune nephropathy Immunologic diseases. Allergy Biao Huang verfasserin aut Yi Zhang verfasserin aut Liang Wang verfasserin aut Qingqing Wu verfasserin aut Ting Li verfasserin aut Jue Zhang verfasserin aut Qiuhua Zhang verfasserin aut Huiming Sheng verfasserin aut Jiandong Bao verfasserin aut Zhigang Hu verfasserin aut In Frontiers in Immunology Frontiers Media S.A., 2011 11(2020) (DE-627)657998354 (DE-600)2606827-8 16643224 nnns volume:11 year:2020 https://doi.org/10.3389/fimmu.2020.00837 kostenfrei https://doaj.org/article/bb78e04da73a42688a1189320e2a185c kostenfrei https://www.frontiersin.org/article/10.3389/fimmu.2020.00837/full kostenfrei https://doaj.org/toc/1664-3224 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020
language	English
source	In Frontiers in Immunology 11(2020) volume:11 year:2020
sourceStr	In Frontiers in Immunology 11(2020) volume:11 year:2020
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	phospholipase A2 receptor autoantibodies thyroid disease autoimmune nephropathy Immunologic diseases. Allergy
isfreeaccess_bool	true
container_title	Frontiers in Immunology
authorswithroles_txt_mv	Biao Huang @@aut@@ Yi Zhang @@aut@@ Liang Wang @@aut@@ Qingqing Wu @@aut@@ Ting Li @@aut@@ Jue Zhang @@aut@@ Qiuhua Zhang @@aut@@ Huiming Sheng @@aut@@ Jiandong Bao @@aut@@ Zhigang Hu @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	657998354
id	DOAJ008658684
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ008658684</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310012822.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fimmu.2020.00837</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ008658684</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbb78e04da73a42688a1189320e2a185c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Biao Huang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phospholipase A2 receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoantibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">thyroid disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoimmune</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nephropathy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Biao Huang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yi Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liang Wang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qingqing Wu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ting Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jue Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qiuhua Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Huiming Sheng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jiandong Bao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhigang Hu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Immunology</subfield><subfield code="d">Frontiers Media S.A., 2011</subfield><subfield code="g">11(2020)</subfield><subfield code="w">(DE-627)657998354</subfield><subfield code="w">(DE-600)2606827-8</subfield><subfield code="x">16643224</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2020</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fimmu.2020.00837</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bb78e04da73a42688a1189320e2a185c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/article/10.3389/fimmu.2020.00837/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1664-3224</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2020</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Biao Huang
spellingShingle	Biao Huang misc RC581-607 misc phospholipase A2 receptor misc autoantibodies misc thyroid disease misc autoimmune misc nephropathy misc Immunologic diseases. Allergy Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy
authorStr	Biao Huang
ppnlink_with_tag_str_mv	@@773@@(DE-627)657998354
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-607
illustrated	Not Illustrated
issn	16643224
topic_title	RC581-607 Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy phospholipase A2 receptor autoantibodies thyroid disease autoimmune nephropathy
topic	misc RC581-607 misc phospholipase A2 receptor misc autoantibodies misc thyroid disease misc autoimmune misc nephropathy misc Immunologic diseases. Allergy
topic_unstemmed	misc RC581-607 misc phospholipase A2 receptor misc autoantibodies misc thyroid disease misc autoimmune misc nephropathy misc Immunologic diseases. Allergy
topic_browse	misc RC581-607 misc phospholipase A2 receptor misc autoantibodies misc thyroid disease misc autoimmune misc nephropathy misc Immunologic diseases. Allergy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Frontiers in Immunology
hierarchy_parent_id	657998354
hierarchy_top_title	Frontiers in Immunology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)657998354 (DE-600)2606827-8
title	Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy
ctrlnum	(DE-627)DOAJ008658684 (DE-599)DOAJbb78e04da73a42688a1189320e2a185c
title_full	Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy
author_sort	Biao Huang
journal	Frontiers in Immunology
journalStr	Frontiers in Immunology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
author_browse	Biao Huang Yi Zhang Liang Wang Qingqing Wu Ting Li Jue Zhang Qiuhua Zhang Huiming Sheng Jiandong Bao Zhigang Hu
container_volume	11
class	RC581-607
format_se	Elektronische Aufsätze
author-letter	Biao Huang
doi_str_mv	10.3389/fimmu.2020.00837
author2-role	verfasserin
title_sort	phospholipase a2 receptor autoantibodies as a novel serological biomarker for autoimmune thyroid disease associated nephropathy
callnumber	RC581-607
title_auth	Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy
abstract	Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy.
abstractGer	Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy.
abstract_unstemmed	Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy
url	https://doi.org/10.3389/fimmu.2020.00837 https://doaj.org/article/bb78e04da73a42688a1189320e2a185c https://www.frontiersin.org/article/10.3389/fimmu.2020.00837/full https://doaj.org/toc/1664-3224
remote_bool	true
author2	Biao Huang Yi Zhang Liang Wang Qingqing Wu Ting Li Jue Zhang Qiuhua Zhang Huiming Sheng Jiandong Bao Zhigang Hu
author2Str	Biao Huang Yi Zhang Liang Wang Qingqing Wu Ting Li Jue Zhang Qiuhua Zhang Huiming Sheng Jiandong Bao Zhigang Hu
ppnlink	657998354
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3389/fimmu.2020.00837
callnumber-a	RC581-607
up_date	2024-07-03T19:19:44.400Z
_version_	1803586774660808704
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ008658684</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310012822.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fimmu.2020.00837</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ008658684</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbb78e04da73a42688a1189320e2a185c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Biao Huang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aims: To develop a highly sensitive immunoassay for PLA2R autoantibodies and study the relationship between PLA2R autoantibodies and autoimmune thyroid disease-associated nephropathy.Methods: We applied a highly sensitive time-resolved fluoroimmunoassay to quantitatively detect the concentration of phospholipase A2 receptor (PLA2R) antibodies in the serum of patients with Graves' disease, Hashimoto's thyroiditis (HT), nephrotic patients with idiopathic membranous nephropathy (IMN), and normal controls. We immunohistochemically analyzed the existing PLA2R target antigen in the thyroid tissue of patients with Graves' disease and HT, as well as the nephridial tissue of nephrotic patients with IMN.Results: PLA2R antibody concentrations in the serum of normal controls, patients with nodular goiter, Graves' disease, and HT, as well as patients with IMN were 1.13 ± 0.43, 1.07 ± 0.22, 2.12 ± 2.11, 8.07 ± 4.74, and 15.91 ± 19.50 mg/L, respectively. PLA2R antibody concentration in the serum and the area under the receiver operating characteristic curve in patients with HT and IMN were increased significantly. Immunohistochemistry revealed obvious staining of PLA2R in tissues from patients with HT, with a positive rate of 66.67%.Conclusions: PLA2R is a potential pathogenic target antigen for HT, and the production of PLA2R antibodies may cause autoimmune thyroid disease-associated nephropathy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phospholipase A2 receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoantibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">thyroid disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoimmune</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nephropathy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Biao Huang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yi Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liang Wang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qingqing Wu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ting Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jue Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qiuhua Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Huiming Sheng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jiandong Bao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhigang Hu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Immunology</subfield><subfield code="d">Frontiers Media S.A., 2011</subfield><subfield code="g">11(2020)</subfield><subfield code="w">(DE-627)657998354</subfield><subfield code="w">(DE-600)2606827-8</subfield><subfield code="x">16643224</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2020</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fimmu.2020.00837</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bb78e04da73a42688a1189320e2a185c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/article/10.3389/fimmu.2020.00837/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1664-3224</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2020</subfield></datafield></record></collection>
score	7.39935

Nicht das Richtige dabei?

Schreiben Sie uns!

Phospholipase A2 Receptor Autoantibodies as a Novel Serological Biomarker for Autoimmune Thyroid Disease Associated Nephropathy

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?